101 related articles for article (PubMed ID: 8280707)
21. Recombinant vaccinia virus expressing IL-2 generates effective anti-tumor responses in an orthotopic murine model of head and neck carcinoma.
Dasgupta S; Tripathi PK; Bhattacharya-Chatterjee M; O'Malley B; Chatterjee SK
Mol Ther; 2003 Aug; 8(2):238-48. PubMed ID: 12907146
[TBL] [Abstract][Full Text] [Related]
22. Vaccinia colon oncolysate immunotherapy for murine hepatic metastases can be modulated with low-dose interleukin-2. Third place winner: Conrad Jobst Award.
Barnavon Y; Iwaki H; Bash JA; Wallack MK
Am Surg; 1988 Dec; 54(12):696-701. PubMed ID: 3264127
[TBL] [Abstract][Full Text] [Related]
23. Antitumor activity and immune responses induced by a recombinant carcinoembryonic antigen-vaccinia virus vaccine.
Kantor J; Irvine K; Abrams S; Kaufman H; DiPietro J; Schlom J
J Natl Cancer Inst; 1992 Jul; 84(14):1084-91. PubMed ID: 1619682
[TBL] [Abstract][Full Text] [Related]
24. Local delivery of recombinant vaccinia virus expressing secondary lymphoid chemokine (SLC) results in a CD4 T-cell dependent antitumor response.
Flanagan K; Glover RT; Hörig H; Yang W; Kaufman HL
Vaccine; 2004 Jul; 22(21-22):2894-903. PubMed ID: 15246626
[TBL] [Abstract][Full Text] [Related]
25. [Immunogenic properties of recombinant vaccinia virus containing the human IL-2 gene].
Babkin IV; Riazankin IA; Lebedev LR; Bulychev LE; Nesterov AE; Nosareva OV; Babkina IN
Vopr Virusol; 2008; 53(1):27-31. PubMed ID: 18318132
[TBL] [Abstract][Full Text] [Related]
26. Intratumoral injection of bone-marrow derived dendritic cells engineered to produce interleukin-12 induces complete regression of established murine transplantable colon adenocarcinomas.
Melero I; Duarte M; Ruiz J; Sangro B; Galofré J; Mazzolini G; Bustos M; Qian C; Prieto J
Gene Ther; 1999 Oct; 6(10):1779-84. PubMed ID: 10516729
[TBL] [Abstract][Full Text] [Related]
27. [Experimental study of the immuno-protective activity of recombinant vaccinia virus expressing HPV58 E7].
Luo LQ; Li J; Liu X; Zhang YH
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2003 Feb; 25(1):43-6. PubMed ID: 12905606
[TBL] [Abstract][Full Text] [Related]
28. Adoptive immunotherapy as an in vivo model to explore antitumor mechanisms induced by a recombinant anticancer vaccine.
Abrams SI; Hodge JW; McLaughlin JP; Steinberg SM; Kantor JA; Schlom J
J Immunother; 1997 Jan; 20(1):48-59. PubMed ID: 9101413
[TBL] [Abstract][Full Text] [Related]
29. Virological and preclinical characterization of a dendritic cell targeting, integration-deficient lentiviral vector for cancer immunotherapy.
Odegard JM; Kelley-Clarke B; Tareen SU; Campbell DJ; Flynn PA; Nicolai CJ; Slough MM; Vin CD; McGowan PJ; Nelson LT; Ter Meulen J; Dubensky TW; Robbins SH
J Immunother; 2015; 38(2):41-53. PubMed ID: 25658613
[TBL] [Abstract][Full Text] [Related]
30. Vaccine therapy of established tumors in the absence of autoimmunity.
Hodge JW; Grosenbach DW; Aarts WM; Poole DJ; Schlom J
Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742
[TBL] [Abstract][Full Text] [Related]
31. A double recombinant adenovirus expressing the costimulatory molecule B7-1 (murine) and human IL-2 induces complete tumor regression in a murine breast adenocarcinoma model.
Emtage PC; Wan Y; Bramson JL; Graham FL; Gauldie J
J Immunol; 1998 Mar; 160(5):2531-8. PubMed ID: 9498799
[TBL] [Abstract][Full Text] [Related]
32. Antitumor effects of interleukin-2 gene-modified fibroblasts in an orthotopic colon cancer model.
Terasawa H; Tanimura H; Nakamori M; Tsunoda T; Iwahashi M; Tani M; Yamaue H
Jpn J Cancer Res; 1999 Sep; 90(9):1000-6. PubMed ID: 10551331
[TBL] [Abstract][Full Text] [Related]
33. Complex interactions between the replicating oncolytic effect and the enzyme/prodrug effect of vaccinia-mediated tumor regression.
McCart JA; Puhlmann M; Lee J; Hu Y; Libutti SK; Alexander HR; Bartlett DL
Gene Ther; 2000 Jul; 7(14):1217-23. PubMed ID: 10918490
[TBL] [Abstract][Full Text] [Related]
34. Immunization against endogenous retroviral tumor-associated antigens.
Kershaw MH; Hsu C; Mondesire W; Parker LL; Wang G; Overwijk WW; Lapointe R; Yang JC; Wang RF; Restifo NP; Hwu P
Cancer Res; 2001 Nov; 61(21):7920-4. PubMed ID: 11691813
[TBL] [Abstract][Full Text] [Related]
35. [Effects of hMIP-1beta gene modification on in vivo tumorigenicity and vaccine efficacy of tumor cells].
Luo XL; Xie YA; Kuang ZP; Wu JN; Liang AM
Zhonghua Zhong Liu Za Zhi; 2008 Feb; 30(2):97-102. PubMed ID: 18646689
[TBL] [Abstract][Full Text] [Related]
36. Adenovirus-mediated TNF-alpha gene transfer induces significant tumor regression in mice.
Wright P; Braun R; Babiuk L; Littel-van den Hurk SD; Moyana T; Zheng C; Chen Y; Xiang J
Cancer Biother Radiopharm; 1999 Feb; 14(1):49-57. PubMed ID: 10850287
[TBL] [Abstract][Full Text] [Related]
37. Application of an interleukin 2 slow delivery system to the immunotherapy of established murine colon 26 adenocarcinoma liver metastases.
Fujiwara T; Sakagami K; Matsuoka J; Shiozaki S; Uchida S; Fujioka K; Takada Y; Onoda T; Orita K
Cancer Res; 1990 Nov; 50(21):7003-7. PubMed ID: 2208166
[TBL] [Abstract][Full Text] [Related]
38. Immunotherapy of experimental metastases by vaccination with interleukin gene-transduced adenocarcinoma cells sharing tumor-associated antigens. Comparison between IL-12 and IL-2 gene-transduced tumor cell vaccines.
Rodolfo M; Zilocchi C; Melani C; Cappetti B; Arioli I; Parmiani G; Colombo MP
J Immunol; 1996 Dec; 157(12):5536-42. PubMed ID: 8955204
[TBL] [Abstract][Full Text] [Related]
39. Recombinant DNA vaccines protect against tumors that are resistant to recombinant vaccinia vaccines containing the same gene.
Chen CH; Wang TL; Ji H; Hung CF; Pardoll DM; Cheng WF; Ling M; Wu TC
Gene Ther; 2001 Jan; 8(2):128-38. PubMed ID: 11313782
[TBL] [Abstract][Full Text] [Related]
40. Specific immunotherapy using a recombinant vaccinia virus expressing human carcinoembryonic antigen.
Kantor J; Abrams S; Irvine K; Snoy P; Kaufman H; Schlom J
Ann N Y Acad Sci; 1993 Aug; 690():370-3. PubMed ID: 8368759
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
